Clinical Report: Ferroptosis Induction by RSPO2 Inhibits Breast Cancer Progression
Overview
This study identifies RSPO2 as a tumor suppressor in breast cancer, demonstrating that its overexpression leads to ferroptosis through PTBP1 degradation.
Background
Breast cancer is the most common malignant tumor globally, with significant heterogeneity complicating treatment. Understanding the molecular mechanisms driving breast cancer progression is crucial.
Data Highlights
RSPO2 was downregulated in malignant breast cancer tissues. Overexpression of RSPO2 suppressed cell proliferation, migration, and invasion in vitro and inhibited tumor growth in vivo.
Key Findings
['RSPO2 expression is downregulated in malignant breast cancer tissues.', 'Restoring RSPO2 expression suppresses cell proliferation, migration, and invasion.', 'RSPO2 recruits TRIM21 to promote PTBP1 ubiquitination and degradation.', 'PTBP1 enhances FSP1 mRNA stability, which is reduced by RSPO2 overexpression.', 'RSPO2 overexpression triggers ferroptosis, evidenced by ROS accumulation and GSH depletion.']
Clinical Implications
Further exploration of ferroptosis in breast cancer could lead to innovative approaches.
Conclusion
This research elucidates the role of RSPO2 in breast cancer progression through ferroptosis induction.
